These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 20569086

  • 1. Comparison of orlistat treatment and placebo in obese type 2 diabetic patients.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, D'Angelo A, Fogari E, Palumbo I, Randazzo S, Cicero AF.
    Expert Opin Pharmacother; 2010 Aug; 11(12):1971-82. PubMed ID: 20569086
    [Abstract] [Full Text] [Related]

  • 2. Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients.
    Derosa G, Maffioli P, Ferrari I, D'Angelo A, Fogari E, Palumbo I, Randazzo S, Cicero AF.
    Fundam Clin Pharmacol; 2011 Oct; 25(5):642-51. PubMed ID: 21077943
    [Abstract] [Full Text] [Related]

  • 3. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes.
    Derosa G, Cicero AF, D'Angelo A, Fogari E, Maffioli P.
    J Clin Pharm Ther; 2012 Apr; 37(2):187-95. PubMed ID: 21812797
    [Abstract] [Full Text] [Related]

  • 4. Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients.
    Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, D'Angelo A, Cicero AF.
    J Clin Pharm Ther; 2011 Oct; 36(5):592-601. PubMed ID: 21070297
    [Abstract] [Full Text] [Related]

  • 5. Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients.
    Derosa G, Maffioli P, Ferrari I, D'Angelo A, Fogari E, Palumbo I, Randazzo S, Cicero AF.
    Endocr J; 2010 Oct; 57(9):777-86. PubMed ID: 20683173
    [Abstract] [Full Text] [Related]

  • 6. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Impact of weight loss on adipocytokines, C-reactive protein and insulin sensitivity in hypertensive women with central obesity.
    Borges RL, Ribeiro-Filho FF, Carvalho KM, Zanella MT.
    Arq Bras Cardiol; 2007 Dec; 89(6):409-14. PubMed ID: 18317625
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women.
    Bougoulia M, Triantos A, Koliakos G.
    Hormones (Athens); 2006 Dec; 5(4):259-69. PubMed ID: 17178701
    [Abstract] [Full Text] [Related]

  • 11. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.
    Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, Hollander P.
    Diabetes Care; 2002 Jun; 25(6):1033-41. PubMed ID: 12032111
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet.
    Derosa G, Mugellini A, Ciccarelli L, Fogari R.
    Clin Ther; 2003 Apr; 25(4):1107-22. PubMed ID: 12809960
    [Abstract] [Full Text] [Related]

  • 14. Orlistat for obesity: benefits beyond weight loss.
    Hsieh CJ, Wang PW, Liu RT, Tung SC, Chien WY, Chen JF, Chen CH, Kuo MC, Hu YH.
    Diabetes Res Clin Pract; 2005 Jan; 67(1):78-83. PubMed ID: 15620437
    [Abstract] [Full Text] [Related]

  • 15. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.
    Finer N, James WP, Kopelman PG, Lean ME, Williams G.
    Int J Obes Relat Metab Disord; 2000 Mar; 24(3):306-13. PubMed ID: 10757623
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin.
    Berne C, Orlistat Swedish Type 2 diabetes Study Group.
    Diabet Med; 2005 May; 22(5):612-8. PubMed ID: 15842517
    [Abstract] [Full Text] [Related]

  • 18. Effect of orlistat on cardiovascular disease risk in obese adults.
    Swinburn BA, Carey D, Hills AP, Hooper M, Marks S, Proietto J, Strauss BJ, Sullivan D, Welborn TA, Caterson ID.
    Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142
    [Abstract] [Full Text] [Related]

  • 19. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
    Derosa G, Cicero AF, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Ferrari I, Gravina A, Fogari R.
    Hypertens Res; 2006 Nov; 29(11):849-56. PubMed ID: 17345784
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.